Pembrolizumab (Keytruda®) for Classical Hodgkin Lymphoma

Assessment Status Rapid Review Complete
Drug Pembrolizumab
Brand Keytruda®
Indication As monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant and brentuximab vedotin (BV), or who are transplant-ineligible and have failed BV.
Assessment Process
Rapid review commissioned 06/12/2017
Rapid review completed 21/12/2017
Rapid review outcome Full pharmacoeconomic assessment recommended at the submitted price.

The HSE has approved reimbursement following confidential price negotiations – November 2018.